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Certolizumab pegol plus methotrexate
5-year results from the rheumatoid arthritis
prevention of structural damage (RAPID) 2
randomized controlled trial and long-term
extension in rheumatoid arthritis patients
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Robert Landewé7, Boulos Haraoui8, Catherine Arendt9, Irina Mountian9, David Carter9 and Désirée van der Heijde10
Abstract
Introduction: As patients with rheumatoid arthritis (RA) receive treatment with anti-tumour necrosis factors over
several years, it is important to evaluate their long-term safety and efficacy. The objective of this study was to
examine the safety and benefits of certolizumab pegol (CZP)+methotrexate (MTX) treatment for almost 5 years in
patients with RA.
Methods: Patients who completed the 24-week Rheumatoid Arthritis Prevention of Structural Damage (RAPID) 2
randomized controlled trial (RCT; NCT00160602), or who were American College of Rheumatology (ACR) 20
non-responders at Week 16, entered the open-label extension (OLE; NCT00160641). After ≥6 months treatment with
CZP 400 mg every two weeks (Q2W), dose was reduced to 200 mg Q2W, the approved maintenance dose. Safety data
are presented from all patients who received ≥1 dose CZP (Safety population, n=612). Efficacy data are presented to
Week 232 for the intent-to-treat (ITT, n=492) and Week 24 CZP RCT Completer (n=342) populations, and through 192
weeks of dose-reduction for the Dose-reduction population (patients whose CZP dose was reduced to 200 mg,
n=369). Radiographic progression (modified total Sharp score change from RCT baseline >0.5) to Week 128 is reported
for the Week 24 CZP Completers.
Results: In the RCT, 619 patients were randomized to CZP+MTX (n=492) or placebo+MTX (n=127). Overall, 567
patients (91.6%) entered the OLE: 447 CZP and 120 placebo patients. Of all randomized patients, 358 (57.8%) were
ongoing at Week 232. Annual drop-out rates during the first four years ranged from 8.4–15.0%. Event rates per 100
patient-years were 163.0 for adverse events (AEs) and 15.7 for serious AEs. Nineteen patients (3.1%) had fatal AEs
(incidence rate=0.8). Clinical improvements in the RCT were maintained to Week 232 in the CZP Completers: mean
Disease Activity Score 28 (Erythrocyte Sedimentation Rate) change from baseline was −3.4 and ACR20/50/70 responses
68.4%/47.1%/25.1% (non-responder imputation). Similar improvements observed in the ITT were maintained following
dose-reduction. 73.2% of CZP Completers had no radiographic progression at Week 128.
Conclusions: In patients with active RA despite MTX therapy, CZP was well tolerated, with no new safety signals
identified. CZP provided sustained improvements in clinical outcomes for almost 5 years.
Trial registration: ClinicalTrials.gov, NCT00160602 and NCT00160641. Registered 8 September 2005.
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Introduction
Anti-tumor necrosis factors (anti-TNFs) are well-established
therapies for the treatment of active rheumatoid arthritis
(RA) [1]. Nonetheless, continued research is needed to
evaluate their long-term efficacy and safety in RA patients.
Certolizumab pegol (CZP) is a PEGylated anti-TNF Fab
employed for treatment of adults with moderate-to-severe
RA. Results from the Rheumatoid arthritis prevention of
structural damage (RAPID) 2 randomized controlled trial
(RCT) demonstrated rapid and significant improvements
in signs and symptoms of RA after 24 weeks of treatment,
using a loading dose of 400 mg at weeks 0, 2, and 4
followed by CZP 200 mg or 400 mg every other week
(Q2W) + methotrexate (MTX) [2].
Patients who completed the 24-week RCT or who
withdrew at week 16 due to lack of response were eli-
gible to enter the open-label extension (OLE). In the
OLE, all patients initially received CZP 400 mg Q2W +
MTX for ≥6 months, followed by a dose reduction to
200 mg Q2W, the approved maintenance dose of CZP.
The primary objective of this paper is to assess the long-
term safety and efficacy of CZP + MTX treatment up to
232 weeks (approximately 4.5 years) in patients with ac-
tive RA. Additionally, we report efficacy analyses for pa-
tients who experienced dose reduction during the OLE
and explore whether the timing of the initial response to
CZP or lack of response upon OLE entry had an impact
on long-term outcomes.
Methods
Study design
The RAPID 2 OLE (NCT00160641) was conducted at
68 centers across 13 countries; the design of the phase 3
RAPID 2 RCT study has been reported previously [2]. In
the RCT, patients were randomized 2:2:1 to receive one
of two regimens of subcutaneous (sc) CZP (200 mg or
400 mg Q2W) + MTX following administration of the
loading dose (400 mg at weeks 0, 2 and 4), or placebo
Q2W + MTX for 24 weeks. In the OLE, all patients ini-
tially received CZP 400 mg Q2W + MTX for at least 6
months, including patients originally randomized to 200
mg Q2W in the RCT. Following a protocol amendment,
CZP dose was then reduced to 200 mg sc Q2W, the ap-
proved maintenance dose of CZP. This amendment was
driven by data from RAPID 1 [3] and RAPID 2 [2],
which demonstrated that 400 mg Q2W provided no
additional benefit compared with 200 mg Q2W.
Both studies were conducted in accordance with Inter-
national Conference on Harmonisation-Good Clinical
Practice requirements and the ethical principles that
have their origin in the principles of the Declaration of
Helsinki. Informed patient consent and all appropriate
ethical committee approvals were obtained for both
studies. Full details of the ethical bodies and committees
that approved the study for each center are provided in
“Acknowledgements”.
Patients
Inclusion and exclusion criteria for the RCT are reported
in the primary publication [2]. In brief, eligible patients
had active RA of ≥6 months’ duration prior to screening
and had received MTX therapy for ≥6 months (stable
dosage of ≥10 mg/week for ≥2 months prior to baseline).
Changes in MTX dose were permitted during the OLE if
clinically indicated, but MTX discontinuation was not.
Disease-modifying anti-rheumatic drugs (DMARDs) other
than MTX were not permitted during the RCT, but were
allowed during the OLE; other biological therapies were
prohibited throughout.
Two groups of patients were eligible to enter the OLE:
(1) CZP or placebo patients who completed the 24-week
RCT and (2) CZP or placebo patients who were American
College of Rheumatologists (ACR)20 non-responders at
both weeks 12 and 14 in the RCT, and were required to
withdraw from the RCT at week 16.
Patient retention
Kaplan-Meier analysis was used to estimate patient re-
tention in the CZP intention-to-treat (ITT) population.
This included patients who withdrew for any reason
compared with those who withdrew due to an adverse
event (AE) or lack of efficacy only. The annual dropout
rate in the CZP ITT population for each year of the
study is presented as a percentage and was calculated as
follows: (number of patients on treatment at the begin-
ning of the year who were no longer on treatment at the
end of the year)/(total number of patients on treatment
at the beginning of the year) × 100.
Safety assessment and analysis
The primary objective of the OLE was to assess the
long-term safety of CZP + MTX treatment in patients
with active RA. Combined safety data from the RCT and
OLE are presented. The safety population included all
patients who received ≥1 dose of CZP in either the RCT
or OLE. Data are reported from the time of first CZP ex-
posure until last visit or patient withdrawal, plus 12-
weeks follow up (i.e., five times CZP half-life + 14 days
injection, or six times CZP half-life). AEs and serious
AEs (SAEs) were assessed at every visit and classified by
system organ class and preferred term according to the
MedDRA dictionary v9.0. AEs are reported as exposure-
adjusted event rates (ER) and incidence rates (IR) per
100 patient-years (PYs). The most frequent AEs by pre-
ferred term (ER >4.0 per 100 PYs) are also reported.
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Concomitant medication use
Concomitant medication use was measured at each visit
throughout the OLE and coded using the World Health
Organization Drug Dictionary (WHO-DD) 2004/Q4.
Concomitant medications were those starting on or after
the date of first study drug administration in the RAPID
2 RCT and on or before the last on-study visit in the
RAPID 2 OLE. Use of concomitant medications is pre-
sented for all patients who entered the OLE and
summarized by patients taking any non-steroidal anti-
inflammatory drug (NSAID), any corticosteroid, any se-
lective immunosuppressant, any anti-malarial drug, or
any DMARD other than MTX.
Efficacy evaluations
Secondary objectives of the RAPID 2 OLE were assess-
ment of the continued effectiveness of CZP + MTX
treatment in patients with active RA, including analysis
of the impact of treatment on physical wellbeing and qual-
ity of life. Efficacy data and patient-reported outcomes
(PROs) are presented from RAPID 2 RCT baseline to ap-
proximately 4.5 years of CZP treatment (220–232 weeks)
for the following populations: (1) all patients randomized
to CZP (400 mg or 200 mg) in the RCT (CZP ITT popula-
tion), (2) patients randomized to CZP (400 mg or 200 mg)
who completed the 24-week RCT and enrolled in the OLE
(week 24 CZP completers) and (3) patients randomized to
placebo who completed the 24-week RCT and enrolled in
the OLE (week 24 placebo completers).
Disease activity score in 28 joints (erythrocyte sedi-
mentation rate) (DAS28(ESR)) [4], ACR20/ACR50/ACR70
response rates [5], health assessment questionnaire-
disability index (HAQ-DI) [6], patient’s global assess-
ment of disease activity (PtGA) (using 100 mm visual
analog scale (VAS)), and patient’s assessment of arth-
ritis pain (VAS) were measured at entry to OLE, at
weeks 36, 48, 64, and 76, and then every 12 weeks
throughout the OLE. Fatigue (VAS) [7] and short-form-
36 (SF-36) [8] were assessed at baseline, weeks 36, 48,
and 76, and then every 24 weeks throughout the OLE.
Continuous measures are reported as absolute values
or mean changes from RCT baseline. DAS28(ESR) <2.6
remission is also reported. For PROs, minimally clinic-
ally important differences (MCID) were defined as de-
crease of ≥0.22 points from baseline in HAQ-DI scores
[9, 10], improvements ≥2.5 from baseline in SF-36
physical component summary (PCS) scores [11] and
improvements of ≥10 mm in VAS scales [12].
Clinical disease activity index (CDAI) remission
(CDAI ≤2.8), simplified disease activity index (SDAI) re-
mission (SDAI ≤3.3) and ACR-European League Against
Rheumatism (EULAR) 2011 Boolean-based remission cri-
teria [13] using four variables (Boolean 4: swollen joint
count (SJC) and tender joint count (TJC) ≤1, C-reactive
protein (CRP) ≤1 mg/dL and PtGA ≤1) and three variables
(Boolean 3: SJC and TJC ≤1 and PtGA ≤1) were analyzed
post hoc in the CZP ITT and week 24 CZP completer
populations. The effects of CZP dose reduction in patients
from the RAPID 2 CZP ITT population who initially re-
ceived CZP 400 mg Q2W + MTX were analyzed post hoc
by efficacy analyses (ACR20/50/70 and DAS28[ESR]) over
192 weeks exposure following dose-reduction.
Patients treated with CZP who completed the RCT
were further stratified into early and late responders.
Early responders were defined as clinical responses at
week 12; later responders as responses at week 24, but
not week 12. Responses were defined in two ways:
ACR20 response (as defined in the protocol) or decrease
from baseline in DAS28(ESR) ≥1.2. Efficacy measures
(ACR50, HAQ-DI, DAS28(ESR)) were compared post
hoc in early vs late responders. Similar analyses also
compared early and late responders with the ACR20 non-
responder population, which included patients treated
with CZP who withdrew at week 16 due to failure to
achieve an ACR20 response, and week 24 CZP completers
who were recorded as not achieving an ACR20 response
at OLE entry.
Assessment of radiographic progression
Radiographs of hands and feet were performed at RCT
baseline and endpoint and/or entry to OLE and weeks
48, 100 and 128. Total and mean changes from baseline
in modified total Sharp score (mTSS) [14] and percent-
age of patients with no radiographic progression (mTSS
change from RCT baseline ≤0.5) are presented for week
24 CZP and placebo completer populations. Additional
post hoc radiographic analyses (mTSS) were compared
in early vs late responders (response defined by decrease
from baseline in DAS28(ESR) ≥1.2).
Statistical analyses
Efficacy results were analyzed descriptively with mean
and standard deviations for continuous variables and
with counts and percentages for binary variables. Ob-
served data are presented alongside imputed data for all
efficacy variables in the CZP completer, CZP ITT and
dose-reduction populations. Non-responder imputation
(NRI) was used to assess ACR responses. Additional
analyses assessed ACR response using mixed model re-
peated measures (MMRM) imputation; the individual
components were imputed using MMRM prior to calcula-
tion of response. Modified NRI was used to assess
DAS28(ESR) low disease activity (LDA) and DAS28(ESR)
remission for timing of response analyses. Missing mTSS
data were imputed by linear extrapolation if at least base-
line and one follow-up radiograph were available.
LOCF/NRI was used to assess DAS28(ESR), CDAI,
SDAI and ACR-EULAR Boolean-based remission in the
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CZP completer and ITT populations. For LOCF/NRI
analyses, missing values during the RCT and missing
values for patients not entering the OLE were imputed
by carrying forward the last available post-baseline com-
posite score. For patients entering the OLE, missing
values during the OLE due to patient withdrawal (AE or
lack of efficacy) or data exclusion after rescue medica-
tion use were imputed as non-remitters, whereas miss-
ing values due to other withdrawal reasons, study
completion, or a missing assessment were imputed by
carrying forward the last available post-RCT entry score.
If still missing, then the value was imputed as non-
remitter.
MMRM imputation was used for all other efficacy var-
iables; the MMRM model specifications had visit, gen-
der, region, rheumatoid factor, and treatment in the
original RCT as fixed effects. If the variable was changed
from baseline, the baseline values were added as covari-
ates. The visits of each patient were the repeated meas-
ure in the model. Additional analyses for all continuous
efficacy variables were assessed using LOCF imputation.
For PRO MCIDs, LOCF/NRI analysis was used.
Binary and continuous variables are presented using
NRI and MMRM imputed values, respectively, because
NRI is a more conservative imputation method than
MMRM for imputing the components of responder vari-
ables. All analyses not shown here are presented as part
of the “Supplementary materials” (Additional file 1).
Where the table or figure number is not indicated, data
shown are present in the text only.
Results
Patient disposition and baseline demographics
In the RCT, 619 patients were randomized: 492 patients
to 400 mg or 200 mg CZP + MTX (CZP ITT popula-
tion) and 127 patients to placebo + MTX. In total, 355
CZP patients (72.2 %) and 17 placebo patients (13.4 %)
completed the RCT, of which 342 CZP patients (week
24 CZP completer population) and all 17 placebo pa-
tients (week 24 placebo completer population) con-
sented to enter the OLE at week 24. In addition to these,
207 patients entered the OLE at week 16 due to lack of
ACR20 response, as per the study protocol. One further
CZP patient withdrew after week 16 due to lack of
ACR20 response and also entered the OLE, as a result of
a windowing rule which caused a narrower group to be
defined for the week 16 withdrawers than were actually
eligible for the OLE (Fig. 1). Altogether, 567 patients
from the RCT entered the OLE. Full patient disposition
throughout the study is summarized in Fig. 1.
During the OLE, 369 patients in the CZP ITT under-
went dose reduction to 200 mg Q2W (dose-reduction
population). By week 232 of CZP treatment, 358 patients
(57.8 % of all randomized patients) remained in the
study. Overall, 612 patients received ≥1 dose of CZP in
either the RAPID 2 RCT or OLE (safety population).
Baseline demographics and disease characteristics
were comparable across all patient populations (CZP
ITT, week 24 CZP completers, week 24 placebo com-
pleters, dose-reduction population and safety population;
Table 1). However, disease duration in the week 24 pla-
cebo completers was approximately half that of the other
patient populations (3.45 years).
Patient retention
Kaplan-Meier survival analyses estimated that 59.9 % of
the CZP ITT population were retained to week 232, ac-
counting for withdrawals for any reason (Fig. 2). If only
withdrawals due to AEs or lack of efficacy were consid-
ered (i.e., patients withdrawing for other reasons were
censored at time of discontinuation), the estimated re-
tention rate after 232 weeks was 73.5 % (Fig. 2). The an-
nual patient dropout rates throughout the study were
15.0 % for year 1, 11.2 % for year 2, 8.4 % for year 3 and
10.6 % for year 4 (Additional file 1: Table S1).
Safety and exposure
Including the time in the RCT, the total median, mean
and maximum durations of exposure to CZP were 1,326,
1,665 and 2,084 days (approximately 189, 238 and 298
weeks), respectively. AEs were reported in 546 out of
612 CZP-exposed patients (89.2 %) during the RCT and
OLE (ER = 163.0) (Table 2). Most frequent AEs were
upper respiratory tract infections, urinary tract infec-
tions and nasopharyngitis (Table 2). Active tuberculosis
infection was reported in 6 patients (1.0 %) and herpes
zoster infection in 10 patients (1.6 %). One pregnancy
was reported during the study, which resulted in a spon-
taneous abortion.
AE incidence was not constant over the whole treat-
ment period (Fig. 3), which is the major assumption for
the use of exposure-adjusted IRs [15, 16]. However, inci-
dence of SAEs remained constant over the majority of
the treatment period (Fig. 3). The overall ER for SAEs
was 15.7 per 100 PYs (IR = 11.2). The most frequent
SAEs (by MedDRA v9.0 system organ class) were serious
infections and infestations (ER = 4.5, IR = 4.1), musculo-
skeletal and connective tissue disorders (ER = 2.8, IR =
2.1), benign, malignant and unspecified tumors (ER =
1.3, IR = 1.2) and injury, poisoning and procedural com-
plications (ER = 1.1, IR = 1.0).
Overall, 119 patients (19.4 %) withdrew due to AEs
(Table 2). There were 19 deaths (3.1 %) during the study,
of which 13 were considered related to the study medi-
cation. As multiple AEs contributed to patient death,
there were 25 fatal AEs in total. Fatal AEs by MedDRA
system organ class (preferred term) included five malig-
nancies (one event each of colon, gastric, pancreatic,
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gastrointestinal and lung malignancy; four considered re-
lated to the study drug), six cardiac disorders (two events
of myocardial ischemia and one each of chronic cardiac
failure, cardiopulmonary failure, ventricular arrhythmia
and myocardial infarction; three related), four nervous sys-
tem disorders (three events of cerebrovascular accidents
and one cerebral hemorrhage; two related), two infec-
tions/infestations (one event each of toxic shock syndrome
and tuberculosis of central nervous system; both related)
one musculoskeletal and connective tissue disorder (one
event of osteonecrosis; related), and one hepatobiliary dis-
order (one event of hepatic cirrhosis; related).
Table 1 Baseline demographics and patient characteristics
Characteristic CZP ITT population
(n = 492)
Week 24 CZP
completers (n = 342)
Week 24 placebo
completers (n = 17)
Dose-reduction
population (n = 369)
Safety population
(n = 612)
Age, mean (SD), years 52.0 (11.4) 51.6 (11.6) 53.2 (16.0) 51.1 (11.3) 51.9 (11.5)
Gender, % female 80.9 82.7 82.4 81.8 81.5
Disease duration, mean (SD), years 6.3 (4.2) 6.5 (4.2) 3.5 (2.3) 6.2 (4.2) 6.2 (4.2)
RF-positive (≥14 IU/ml), % 76.5 75.4 88.2 73.7 76.9
Tender/painful joint count, mean (SD) 30.1 (14.2) 30.5 (14.5) 33.4 (12.1) 29.9 (13.9) 30.2 (14.0)
Swollen joint count, mean (SD) 20.7 (9.9) 20.7 (10.1) 24.2 (8.2) 20.6 (10.1) 21.0 (9.9)
Pain VAS, mean (SD) 61.2 (19.7) 60.6 (19.8)a 59.1 (21.6) 61.2 (19.5)b 60.9 (20.3)c
HAQ-DI, mean (SD) 1.6 (0.6) 1.6 (0.6) 1.6 (0.5) 1.6(0.6) 1.6 (0.6)d
DAS28(ESR), median (min, max) 6.8 (4, 9)e 6.8 (5, 9)a 7.1 (6, 8) 6.8 (5, 9)b 6.9 (4, 9)f
an = 340; bn = 367; cn = 610; dn = 611; en = 490; fn = 608. CZP certolizumab pegol, ITT intention-to-treat; RF rheumatoid factor, VAS visual analog scale, HAQ-DI
health assessment questionnaire-disability index, DAS28 disease activity score 28, ESR erythrocyte sedimentation rate
Fig. 1 Patient disposition in the Rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and open-label extension
(OLE). Percentages were calculated by dividing number of patients by total number of patients in each treatment arm (n = 127 for placebo, n = 492
for certolizumab pegol (CZP)). aTwo patients randomized in the placebo group received CZP 200 mg in the double-blind phase, and were analyzed as
part of the safety population; bpatients who withdrew due to lack of efficacy at week 16 were eligible to enter the OLE; cat OLE entry all patients
received 400 mg CZP + methotrexate every 2 weeks (Q2W), reduced to CZP 200 mg Q2W after ≥6 months; dpatients completed 232 weeks of CZP
treatment from the first dose; enumber of withdrawers who entered the OLE differs from the number of week-16 withdrawers due to a windowing
rule that resulted in a narrower group being defined for the week-16 withdrawers than actually were eligible for the OLE; week-16 withdrawers were
defined as those who withdrew due to lack of efficacy at week 16, whereas withdrawers entering the RAPID 2 OLE included all withdrawers who
entered the OLE, as recorded in the subject status evaluation. AE adverse event, ITT intention-to-treat, MTX methotrexate, RCT randomized controlled trial
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Concomitant medication use
During the OLE portion of the study, the majority of pa-
tients who entered the OLE (n = 567) used concomitant
NSAID medication (521 patients, 91.9 %), and just over
two thirds of patients used corticosteroids (385 patients,
67.9 %) (Additional file 1: Table S2). DMARDs other
than MTX were permitted in the OLE and were used by
133 patients (23.5 %) during the study. Very few patients
used selective immunosuppressant agents or anti-malarial
drugs (six patients, 1.1 % and two patients, 0.4 %,
respectively).
Clinical efficacy
Improvements in disease activity (DAS28(ESR)) in the
OLE were observed to week 232 in both the CZP ITT
and week 24 CZP completer populations (Fig. 4a). Both
populations had a mean DAS28(ESR) of 6.8 at RAPID 2
RCT baseline; after 36 weeks of CZP treatment this was
reduced to 4.1 and 3.8, respectively, in the CZP ITT and
CZP completers, and further reduced to 3.5 and 3.4 by
week 232 (Fig. 4a, Additional file 1: Table S3A; MMRM
imputation). After 232 weeks of CZP treatment, mean
changes from baseline in DAS28(ESR) were −3.3 and
−3.4, respectively (Additional file 1: Table S3B; MMRM
imputation) and DAS28(ESR) remission rates were 14.1
% and 17.3 %. Observed DAS28(ESR) data and data
imputed using MMRM were similar (Fig. 4a), as were
data imputed using LOCF (Additional file 1: Figure S1).
ACR response rates observed during the RAPID 2
RCT were maintained until week 232 of the study
(Fig. 4c and d). Although the true meaning of long-term
ACR response over time is not fully clear, ACR20 was
the primary endpoint and ACR50 and ACR70 response
rates were secondary endpoints for the initial part of this
study, therefore it is important to evaluate if these re-
sponses are stable over time. Week 232 ACR20, ACR50
and ACR70 response rates assessed by NRI were 58.9 %,
38.6 % and 20.1 % in the CZP ITT population and 68.4 %,
47.1 % and 25.1 % in the week-24 CZP completers. As ex-
pected, observed and MMRM response rates were higher
than NRI-assessed ACR response rates (Additional file 1:
Figure S1C and D). In the week-24 placebo completer
population, NRI-assessed ACR20 response rates observed
at week 36 (88.2 %) decreased by week 232 (64.7 %),
whereas ACR50 and ACR70 response rates improved with
long-term CZP treatment in the OLE from 47.1 % and
23.5 % at week 36 to 64.7 % and 35.3 % by week 232
(Additional file 1: Table S3C-E).
In the CZP ITT and week-24 CZP completer popula-
tions, similar percentages of patients achieved ACR-
EULAR Boolean remission at week 232 (Boolean 4: CZP
ITT = 7.5 %, CZP completers = 9.9 %; Boolean 3: CZP
ITT = 8.5 %, CZP completers = 11.1 %) and SDAI and
Fig. 2 Kaplan-Meier plot of time to withdrawal for any reason and due to lack of efficacy or adverse event from start of the randomized controlled
trial (RCT) for the certolizumab pegol (CZP) intention-to-treat (ITT) population (n =492). AE adverse event, MTX methotrexate, OLE open-label extension
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CDAI remission at week 232 (SDAI: CZP ITT = 10.2 %,
CZP completers = 12.9 %; CDAI: CZP ITT = 10.4 %,
CZP completers = 13.2 %).
Dose reduction
Clinical improvements were maintained following the
reduction of CZP dose from 400 mg to 200 mg Q2W,
the approved maintenance dose of CZP. At the dose-
reduction visit, mean DAS28(ESR) was 3.6 in the dose-
reduction population (n =369), which was sustained
through 192 weeks of CZP 200 mg Q2W (Fig. 5a,
MMRM imputation). Observed and LOCF DAS28(ESR)
results were very similar to those imputed by MMRM
(Additional file 1: Figure S2). ACR response rates were
also maintained throughout the dose-reduction period
(Fig. 5b and c).
Timing of response to CZP
When week-24 CZP completers were stratified by timing
of response to CZP, there were 287 early week-12
ACR20 responders and 280 early DAS28 responders. At
week 24, there were 30 late ACR20 responders and 47
late DAS28 responders. In total, 125 CZP-treated
patients were ACR20 non-responders at OLE entry
(Additional file 1: Table S4). Baseline characteristics
were similar between early and late responder groups
(Additional file 1: Table S4).
In general, early responders had better long-term clin-
ical outcomes than later responders (Fig. 6a). Higher
ACR50 responses and better DAS28(ESR) scores were
observed at week 232, with a greater percentage of early
responders achieving DAS28(ESR) LDA or DAS28(ESR)
remission (Fig. 6a). This was true when responses were
defined by ACR20 response, or by decrease from base-
line in DAS28(ESR) ≥1.2. In contrast, the percentage of
patients reporting improvements in HAQ-DI ≥ the min-
imally clinically important difference (MCID) remained
similar (Fig. 6a).
At week 232, 20.0 % of the late ACR20 responders
achieved DAS28(ESR) LDA and 10.0 % achieved
DAS28(ESR) remission compared with 20.0 % and 8.8 %,
Table 2 Summary of AEs and SAEs in the RAPID 2 RCT and OLE (safety population, n = 612)
Patients, number (%) Total number
of events
Event rate per
100 PYsa
Incidence rate per
100 PYs
Total AEs 546 (89.2) 3789 163.0 87.4
Infections and infestationsb 420 (68.6) 1257 54.1 36.4
Tuberculosisc 6 (1.0) 6 0.26 0.26
Herpes zosterc 10 (1.6) 11 0.47 0.43
Neoplasms (benign, malignant and unspecified)b 19 (3.1) 20 0.9 0.8
Most frequent AEs by preferred term (ER >4.0 per 100 PYs)
Upper respiratory tract infections 93 (15.2) 154 6.6 4.4
Nasopharyngitis 67 (10.9) 101 4.3 3.1
Urinary tract infections 65 (10.6) 94 4.0 3.0
AEs leading to withdrawal 119 (19.4) 157 N/A 5.2
AEs leading to death by system organ class 19 (3.1) 25 N/A 0.8
Neoplasms (benign, malignant and unspecified) 5 (0.8) 5 N/A 0.2
Cardiac disorders 4 (0.7) 6 N/A 0.2
Nervous system disorders 4 (0.7) 4 N/A 0.2
Injury, poisoning and procedural complications 4 (0.7) 4 N/A 0.2
Infections and infestations 2 (0.3) 2 N/A 0.03
Hepatobiliary disorders 1 (0.2) 1 N/A 0.04
Musculoskeletal and connective tissue disorders 1 (0.2) 1 N/A 0.04
Total SAEs by system organ class 219 (35.8) 364 15.7 11.2
Infections/infestations 90 (14.7) 105 4.5 4.1
Musculoskeletal and connective tissue disorders 47 (7.7) 65 2.8 2.1
Neoplasms (benign, malignant and unspecified) 27 (4.4) 29 1.3 1.2
Injury, poisoning and procedural complications 23 (3.8) 25 1.1 1.0
aEvent rates (ER) were not calculated when an adverse event (AE) occurred in individual patients only once (e.g., in the case of AEs leading to withdrawal or death); in
these cases incidence rates are used; bMedDRA system organ class; cMedDRA preferred term. n/a not available, PYs patient-years, SAE serious adverse event
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Fig. 4 Efficacy variables in the certolizumab pegol (CZP) intention-to-treat (ITT) (n = 492) and week-24 CZP completer populations (n = 342).
a Mean disease activity score in 28 joints (erythrocyte sedimentation rate) (DAS28(ESR)). b Mean health assessment questionnaire-disability index
(HAQ-DI). c American College of Rheumatologists (ACR)20 response. d ACR50 and ACR70 responses. For patients who withdrew at week 16,
observed data from the week-12 visit was also included in the week-24 data (start of open-label extension). MMRM mixed model repeated measures,
NRI non-responder imputation
Fig. 3 Percentage of patients experiencing adverse events (AEs) and serious AEs over each 6-month period from the start of the randomized
controlled trial (safety population, n = 612). SAE serious adverse event
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respectively, in the ACR20 non-responders (Fig. 6a).
Changes from baseline in DAS28(ESR) scores at week 232
were also similar between the ACR20 non-responders and
the CZP ITT population (−2.60 vs −2.91) (Fig. 6b).
When comparing the percentage of patients achieving
ACR50 responses between ACR20 non-responders and
ACR20 late responders, fewer ACR20 non-responders
achieved this level of response at week 232 (20.8 % vs
36.7 %, respectively) (Fig. 6a). Similarly, fewer ACR20
non-responders reported clinically important HAQ-DI
improvements at week 232 than late ACR20 responders
(Fig. 6a). Lack of ACR20 responses at OLE entry also re-
sulted in smaller improvements in HAQ-DI at week 232
compared to the entire CZP ITT population (Fig. 6c).
Radiographic progression
At baseline, the observed mean mTSS score for the
week-24 CZP completers was 33.4 (Fig. 7a); mean
changes from baseline at week 24 and week 128 were
0.62 and 0.79, respectively (Fig. 7b, linear extrapolation).
Even upon linear extrapolation of missing data, the
mean progression over 2 years was approximately 0.5
mTSS units (Fig. 7b, linear extrapolation). The percent-
ages of patients with no radiographic progression (de-
fined as an mTSS change from RCT baseline ≤0.5) were
84.6 % at week 24 and 73.2 % at week 128 (Fig. 7c, linear
extrapolation). In comparison, week-24 placebo com-
pleters had higher mTSS scores than week-24 CZP com-
pleters from baseline throughout the 2-year follow up
period (Figs. 7a and b).
Analysis of the impact of timing of response on radio-
graphic progression showed that long-term radiographic
progression was similar whether patients responded to
CZP at week 12 or week 24. In the early DAS28(ESR) re-
sponders (n = 280), the percentage of patients with no
radiographic progression at week 128 was 72.7 %,
compared with 76.9 % in the late DAS28(ESR) re-
sponders (n = 47).
Physical function and health-related quality of life
Improvements in PROs, including physical function, ob-
served in the RAPID 2 RCT were maintained up to week
Fig. 5 Efficacy variables in patients following dose reduction from certolizumab pegol (CZP) 400 mg every 2 weeks (Q2W) to CZP 200 mg Q2W
(n = 369). a Mean disease activity score in 8 joints (erythrocyte sedimentation rate) (DAS28(ESR)). bAmerican College of Rheumatology (ACR)20
response rates. c ACR50 and ACR70 response rates. This analysis is presented as weeks following dose-reduction visit (Week 0 is defined as the
final efficacy assessment visit where a patient received the CZP 400 mg dose). The sharp decline in patient numbers from week 150 following
dose reduction is due to the per-protocol site closures in countries where CZP became commercially available. MMRM mixed model repeated
measures, NRI non-responder imputation
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220 of CZP treatment (Fig. 4b, Fig. 8, and Additional file
1: Table S5). At 220 weeks, HAQ-DI scores decreased
from a mean of 1.6 at RCT baseline to 0.96 and 0.89 in
the CZP ITT and week-24 completer populations, respect-
ively (Fig. 4b). Changes in pain, PtGA, fatigue and SF-36
PCS scores between RCT baseline and week 36 were also
sustained during the OLE to week 220 (Fig. 8). Observed
and MMRM-imputed data were similar, as were data
imputed by last observation carried forward (LOCF)
(Additional file 1: Figure S3). In both populations, the per-
centages of patients reporting improvements ≥MCID in
HAQ-DI, pain, PtGA, SF-36 PCS and fatigue were main-
tained between weeks 36 and 220 (Fig. 9).
Discussion
Treatment of RA patients with CZP + MTX over 5 years
in this study revealed no new safety signals compared
with the RAPID 1 evaluation of CZP + MTX, [17] and
no increases in AEs or SAEs over time were observed.
Patient retention was high in the RAPID 2 OLE, which
indicates an acceptable tolerability profile and sustained
efficacy of CZP. However, it should be noted that patient
retention in clinical trials is often better than in real-world
clinical practice. Clinical (ACR20/50/70, DAS28(ESR))
and patient-reported (HAQ-DI, PtGA, pain, fatigue, SF-36
PCS) improvements in RA signs, symptoms, and physical
function observed over the 24-week RAPID 2 RCT were
maintained for up to approximately 4.5 years in both the
CZP ITT and week-24 CZP completer populations, con-
sistent with sustained improvements observed in the
RAPID 1 study [17]. Efficacy was also maintained in the
dose-reduction population, demonstrating that CZP 200
mg Q2W + MTX was just as efficacious as CZP 400 mg
Q2W + MTX during the maintenance phase.
Fig. 6 Comparison of clinical efficacy variables between patients responding early or late to certolizumab pegol (CZP), and American College of
Rheumatology (ACR)20 non-responders who re-consented to the open-label extension study. a Percentage of patients achieving clinical outcomes
at week 232 for early or late responders and ACR20 non-responders. b Change from baseline in mean disease activity score in 28 joints (erythrocyte
sedimentation rate) (DAS28(ESR)) score in ACR20 non-responders compared to CZP intention-to-treat (ITT). c Change from baseline in mean health-
assessment questionnaire-disability index (HAQ-DI) score in ACR20 non-responders compared to CZP ITT (last observation carried forward). Response
was defined by ACR20 response or decrease from baseline in DAS28(ESR) ≥1.2. Early responders were those who responded to CZP at week 12 and
late responders were those who responded to CZP at week 24 but not at week 12. aRemission defined as DAS28(ESR) <2.6; blow disease activity (LDA)
defined as DAS28(ESR) ≤3.2; cdefined as a decrease from baseline of ≥0.22 in HAQ-DI. MCID minimal clinically important difference
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Assessment of structural joint damage was docu-
mented for patients over 2 years of CZP treatment fol-
lowing the RAPID 2 RCT, and confirmed that TNF
inhibition, here with CZP, can almost arrest long-term
progression of joint damage in a majority of patients
who completed the initial RCT. Radiographic progres-
sion in the week-24 CZP completers amounted to <1.0
point on the mTSS scale, which corresponds to an esti-
mated irreversible disability increase of <0.01 in the
HAQ-DI [18] over more than 2 years.
Although direct comparisons with other anti-TNFs
are limited by differences in study design and lack of
head-to-head studies, the observed incidences of SAEs
and fatalities in the RAPID 2 OLE were comparable to
long-term studies of other anti-TNFs [19–21]. Similarly,
the IR of serious infections reported in this study (4.1/
100 PYs) is consistent with IRs reported from OLE
studies of other anti-TNFs (ranging from 2.8/100 PYs
to 6.4/100 PYs) [19, 22–24] and also with a recent
pooled safety analysis of clinical CZP trials in RA (3.65/
100 PYs) [25]. In terms of efficacy, ACR response rates
reported for the CZP completers at week 232 also ap-
peared similar to long-term data reported for other
anti-TNFs [19, 24, 26].
Numerically higher ACR50 response rates and lower
DAS28(ESR) scores were observed in early responders
compared to later responders, confirming the import-
ance of an early response to CZP for some long-term
clinical outcomes. These results are consistent with a
previous post-hoc analysis of the RAPID 1 study, which
demonstrated that faster attainment of clinical response
to CZP was associated with improved long-term out-
comes [27]. This is also in line with recent EULAR rec-
ommendations, which state that if no improvement is
observed after 12 weeks of treatment, physicians should
consider adjusting therapy [1]. However, in patients re-
ceiving CZP in the RCT, timing of response made little
difference to the proportions of patients reporting im-
provements in HAQ-DI ≥MCID or experiencing radio-
graphic progression. It should be noted that early
response is likely important for long-term outcomes
with other anti-TNFs and DMARDs, but this may not
have been analyzed in as much detail as the RAPID 1
and 2 studies.
Lack of ACR20 response upon OLE entry appeared to
be important for long-term ACR50 and HAQ-DI out-
comes, but not for DAS28(ESR). A greater percentage of
the later ACR20 responders achieved ACR50 responses
Fig. 7 Assessment of structural damage in week-24 certolizumab pegol (CZP) and placebo (PBO) completers. a Mean modified total Sharp score
(mTSS) (Observed). b Mean change from baseline in mTSS. c Percentage of patients with no radiographic progression. No radiographic progression
was defined as an mTSS change from the randomized controlled trial baseline ≤0.5
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and improvements in HAQ-DI ≥MCID compared with
ACR20 non-responders, whereas the percentages of later
ACR20 responders and ACR20 non-responders achiev-
ing DAS28(ESR) LDA and remission were similar. This
is in line with previous notions on the limitations of the
DAS28 [28, 29]. When compared to the CZP ITT popu-
lation, ACR20 non-responders had similar long-term
improvements in DAS28(ESR) scores, whereas lesser im-
provements were observed in HAQ-DI scores.
Limitations to this study included the relatively small
number of patients who were evaluated. The drop-off in
patient number towards the end of the study due to site
closures in countries where CZP became commercially
available made it impossible to report efficacy outcomes
in patients with treatment duration ≥4.5 years. Addition-
ally, exposure-adjusted IR was a pre-specified safety out-
come in this study; however, the incidence of AEs was not
constant over the treatment period, which is the main as-
sumption for the use of exposure-adjusted IR [15, 16].
A major strength of this report relates to the method
of assessment. Not only were data evaluated in patients
who completed the RCT and consented to enter the
OLE, but an ITT analysis was performed from the start
of the trial, as requested by recent recommendations
[30]. While, expectedly, the response rates were lower in
the ITT than completer analyses, long-term mainten-
ance of response to CZP was fully confirmed as an over-
all result.
Conclusions
In the phase 3 multicenter RAPID 2 RCT and OLE, as-
sessment of CZP as an additional medication to MTX in
patients with active RA confirmed that long-term effi-
cacy of CZP was sustained for almost 5 years, with no
new safety signals observed compared to previous stud-
ies [17]. Efficacy was maintained following dose reduc-
tion from 400 mg to 200 mg Q2W, the approved dose of
CZP, and early response to CZP at week 12 was again as-
sociated with improved long-term clinical outcomes.
The long-term safety and efficacy of CZP reported here
appears comparable to studies with other anti-TNFs
[19–21, 24, 26], however, comparisons are limited due to
differences in study design. These results not only
confirm previously reported short-term data from the
RAPID 2 RCT [2], they additionally support and expand
the results from the RAPID 1 clinical trial and OLE [17].
Fig. 8 Patient-reported outcomes for certolizumab pegol (CZP) intention-to-treat (ITT) and week-24 CZP completer populations. a Change from
baseline in patient’s assessment of arthritic pain. b Change from baseline in patient’s global assessment of disease activity (PtGA). c Change from
baseline in fatigue. d Change from baseline in short form-36 physical component summary (SF-36 PCS). For patients who withdrew at week 16,
observed data from the week-12 visit was also included in the week-24 data (start of open-label extension). MMRM mixed model repeated measures
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